Despite technological advancements even in the medical field, Malaria remains a cause for concern as it is still the number one killer disease in sub-Saharan Africa and number two in the world.
In 2015 alone there were 214 million cases of malaria and 438 000 deaths. Sub-Saharan Africa was home to 88% of these malaria cases and 90% of malaria deaths. (WHO December 2015)
Various measures to prevent and control malaria have been taken, yet the prevalence of malaria incidents is still a major cause for concern. The need for effective treatment of malaria is therefore inevitable.
Over the years, Emzor Pharmaceutical Industries Ltd, has been actively involved in combating malaria through the Manufacturing and distribution of high quality antimalarials like Chloroquine and Sulphadoxine/ Pyrimethamine (Maldox) and in more recent times, the WHO recommended Artemisinin based Combination Therapy (ACT).
In 2009, Emzor launched LOKMAL, her brand of Artemether/ Lumefantrine, which at that time was the first locally manufactured Artemether/ Lumefantrine in the Nigerian Pharmaceutical market. Artemether/ Lumefantrine also happens to be the first choice ACT in Nigeria currently, owing to its high efficacy and excellent safety profile in all classes of patients.
Driven by the vision and philosophy of making unlimited wellness available to all and affordable by all, Emzor has invested immensely in the production and distribution of Lokmal to combat Malaria Nationwide and even beyond the shores of Nigeria, with offices and distribution networks extending to Liberia and Sierra Leone.
Lokmal is manufactured locally here in Nigeria. A proudly Nigerian product with certified quality and manufactured according to internationally recognized GMP. It is a convenient, easy to take antimalarial for the treatment of acute, uncomplicated malaria infection.
One of the challenges faced in effective treatment of malaria is non-adherence/ non-compliance of patients to dosage regimen. This non-compliance could be due to several reasons including, high pill burden and frequency of administration which results into patients omitting doses, taking less medication than is prescribed or discontinuing medication prematurely. This generally results in reduced effectiveness of drugs, treatment failure and higher cost of therapy.
Measures that can be taken to improve patient adherence and compliance include, Improving patient education, Simplifying medication regimen i.e fewer drugs , fewer dose, Simplifying medication package, effective medication reminders and reducing the pill burden.
This has led to the production of LokmalQS combi. LokmalQS combi is a co-pack of higher strength with a fixed dose combination of Artemether/Lumefantrine (80mg/480mg) and our flagship analgesic Emzor Paracetamol tablet (500mg).
This packaging will help patients to always remember to take Paracetamol whenever they are treating malaria and will result in quick resolution of fever, headaches and pains during the course of malaria treatment.
The added value of this packaging lies in the fact that the paracetamol is coming to the patient at no additional cost.
Hence the unique selling proposition for LokmalQS combi are, convenience, enhanced compliance and cost effectiveness.
By Pharm. Gbenga Obaparusi